Articles

Recombinant toxins for cancer treatment

+ See all authors and affiliations

Science  22 Nov 1991:
Vol. 254, Issue 5035, pp. 1173-1177
DOI: 10.1126/science.1683495

Abstract

Recombinant toxins target cell surface receptors and antigens on tumor cells. They kill by mechanisms different from conventional chemotherapy, so that cross resistance to conventional chemotherapeutic agents should not be a problem. Furthermore, they are not mutagens and should not induce secondary malignancies or accelerate progression of benign malignancies. They can be mass-produced cheaply in bacteria as homogeneous proteins. Either growth factor-toxin fusions or antibody-toxin fusions can be chosen, depending on the cellular target.

Related Content